Tech Company Financing Transactions
Adcendo Funding Round
On 5/29/2024, Adcendo raised $17 million in Series A financing from Dawn Biopharma, Gilde Healthcare Partners and Healthcap Venture Capital.
Transaction Overview
Company Name
Announced On
5/29/2024
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to further strengthen its pipeline of first in class ADC assets, including lead asset targeting uPARAP.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
BioInnovation Institute, Ole Maaløes Vej 3, Copenhagen, Capi
Copenhagen, 2200
DK
Copenhagen, 2200
DK
Phone
Undisclosed
Website
Email Address
Overview
Adcendo ApS is a Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers. Antibody-drug conjugates (ADCs) represent an emerging drug modality, directing anticancer therapeutics to malignant cells overexpressing particular surface target molecules. 10+ ADCs are now in routine clinical use for cancer patients, with many more novel ADC assets currently investigated in clinical studies in solid tumors and hematologic malignancies
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Pehl
Chief Operating Officer
Christoffer Nielsen
Chief Scientific Officer
Dominik Mumberg
Chief Technical Officer
Pernille Hemmingsen
Browse more venture capital transactions:
Prev: 5/29/2024: LAfricaMobile venture capital transaction
Next: 5/29/2024: One Energy venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs